Physician profile
Jeremy Chad Everett
NPI 1235415746
$3,703.49
in general payments reported to CMS, 2019-2025
36 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $1,105 · 2021: $423 · 2022: $289 · 2023: $299 · 2024: $257 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $552.81 | 2019-2021 | |
| Abbvie INC. | $487.98 | 2021-2025 | |
| Pfizer INC. | $339.03 | 2019-2025 | |
| Allergan, INC. | $294.51 | 2019-2020 | |
| Novo Nordisk INC | $241.98 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $212.58 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $186.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Nalu Medical, INC. | $145.01 | 2024 | Nalu Neurostimulation System |
| Amgen INC. | $135.12 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $128.41 | 2019 | |
| Merck Sharp & Dohme LLC | $122.47 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $75.14 | 2019-2020 | |
| Astellas Pharma US INC | $64.40 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $63.38 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.43 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $57.61 | 2020-2022 | |
| Shire North American Group INC | $46.71 | 2019 | |
| Amarin Pharma, INC. | $46.46 | 2019-2020 | |
| Corium, LLC | $45.89 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $45.88 | 2019-2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.86 | 2019-2025 | Jardiance |
| Upsher-Smith Laboratories LLC | $40.74 | 2020 | |
| Mylan Specialty L.P. | $40.48 | 2019 | |
| Adlon Therapeutics L.P. | $33.65 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.72 | 2019-2020 | |
| Exact Sciences Corporation | $19.26 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $18.46 | 2023 | |
| Phathom Pharmaceuticals, INC. | $17.84 | 2024-2025 | Voquezna |
| Scilex Pharmaceuticals INC. | $17.82 | 2022 | |
| Avvisto Therapeutics, LLC | $17.44 | 2025 | Cycloset |
| Sanofi-Aventis U.S. LLC | $16.36 | 2020 | |
| Ironshore Pharmaceuticals INC. | $15.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.70 | 2019 | |
| Valeritas, INC. | $12.24 | 2019 | |
| Genentech USA, INC. | $11.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.